Zydus Cadila to reduce its Vaccine price

New Delhi: Zydus Cadila has agreed to bring down the price of its C-19 vaccine to Rs 265 a dose following persistent negotiations by the government but a final deal is yet to be reached, according to the sources said.

Zydus Cadila’s ZyCov-D is the first vaccine cleared by India’s drug regulator for inoculation of those aged 12 years and above.

To administer the needle-free vaccine, a disposable painless jet applicator costing Rs 93 is required for each dose, which would take the price to Rs 358 per dose.

Earlier, the Ahmedabad-based pharma company had proposed a price of Rs 1,900 for its three-dose regimen, sources said.

“The company has brought down the price to Rs 358 for each dose which includes Rs 93, the cost of a disposable jet applicator, following repeated negotiations by the government. A final decision in the matter is likely to be taken this week,” a source in the know of developments told.

The three doses are to be administered 28 days apart, with each dose comprising a shot in both arms. The indigenously developed world’s first DNA-based needle-free C-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Meanwhile, the government is still waiting for the recommendations from the National Technical Advisory Group on Immunisation (NTAGI) for introducing ZyCoV-D in the inoculation drive for adults and children with co-morbidities. NTAGI will provide the protocol and framework for the introduction of this vaccine in the C-19 immunisation drive.

Official sources earlier had said that the pricing of ZyCoV-D would be different from that of Covaxin and Covishield as apart from being a three-dose vaccine, it requires a special pharma jet injector that has to be used for administering the vaccine. That pharma jet injector can be used for administering around 20,000 doses.

“The jet applicator helps the vaccine fluid to penetrate the skin to enter cells of the recipient,” the source said. Zydus Cadila can provide around two crore doses in November, a source had said.

The government is currently procuring two other vaccines, Covishield at Rs 205 per dose and Covaxin at Rs 215 per dose for the national C-19 immunisation programme. Covishield, Covaxin, and Sputnik V are being given to only those above 18 years of age and unlike ZyCoV-D, these are two-dose regimens.

Related Posts

  • Pharma
  • December 23, 2024
  • 73 views
Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

  • Pharma
  • December 23, 2024
  • 107 views
NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

India-Latin America trade and collaboration prospects discussed at Kerala University conference

India-Latin America trade and collaboration prospects discussed at Kerala University conference

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt